Biovest plans new markets

AMPA — In an interview with OneMedRadio, Tampa-based Biovest International Inc. says it is proceeding with plans to gain approval for its BiovaxID product in Canada and the European Union.

In a news release, the company says it plans to apply for approval to market its product in the European Union. It also plans to seek marketing approval for BiovaxID in Canada.

BiovaxID is a personalized cancer vaccine to treat follicular non-Hodgkin's lymphoma.